SJ, Z., DH, W., YW, L., L, H., X, X., M, M., . . . Y, M. (2017). A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects. Dove Medical Press.
Cita Chicago Style (17a ed.)SJ, Zhao, Wang DH, Li YW, Han L, Xiao X, Ma M, Wan DC, Hong A, y Ma Y. A Novel Selective VPAC2 Agonist Peptide-conjugated Chitosan Modified Selenium Nanoparticles with Enhanced Anti-type 2 Diabetes Synergy Effects. Dove Medical Press, 2017.
Cita MLA (8a ed.)SJ, Zhao, et al. A Novel Selective VPAC2 Agonist Peptide-conjugated Chitosan Modified Selenium Nanoparticles with Enhanced Anti-type 2 Diabetes Synergy Effects. Dove Medical Press, 2017.
Precaución: Estas citas no son 100% exactas.